Wasef Nijim, Mohamed Moustafa, Julia Humble, Mohamed Al-Shabrawey
{"title":"Endothelial to mesenchymal cell transition in diabetic retinopathy: targets and therapeutics.","authors":"Wasef Nijim, Mohamed Moustafa, Julia Humble, Mohamed Al-Shabrawey","doi":"10.3389/fopht.2023.1230581","DOIUrl":null,"url":null,"abstract":"<p><p>Diabetic retinopathy (DR) is a result of neurovacular insults from hyperglycemia in diabetes mellitus (DM), and it is one of the top causes of vision loss throughout the modern world. This review article explores the role endothelial to mesenchymal transition (EndMT) has on the pathogenesis of DR. EndMT contributes to the disruption of the blood-retinal barrier, vascular leakage, neovascularization, and fibrosis observed in DR. Risk factors and biomarkers associated with DR severity are discussed, highlighting the importance of early detection and targeted therapies. Current treatments primarily focus on anti-vascular endothelial growth factor (anti-VEGF) agents, corticosteroids, and laser photocoagulation. However, emerging therapeutic strategies aimed at inhibiting EndMT and its downstream effects show promise in preventing the development and progression of DR. Understanding the molecular and cellular mechanisms underlying EndMT in DR provides valuable insights into the disease process and offers potential options for the development of potential treatments.</p>","PeriodicalId":73096,"journal":{"name":"Frontiers in ophthalmology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11182279/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in ophthalmology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/fopht.2023.1230581","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Diabetic retinopathy (DR) is a result of neurovacular insults from hyperglycemia in diabetes mellitus (DM), and it is one of the top causes of vision loss throughout the modern world. This review article explores the role endothelial to mesenchymal transition (EndMT) has on the pathogenesis of DR. EndMT contributes to the disruption of the blood-retinal barrier, vascular leakage, neovascularization, and fibrosis observed in DR. Risk factors and biomarkers associated with DR severity are discussed, highlighting the importance of early detection and targeted therapies. Current treatments primarily focus on anti-vascular endothelial growth factor (anti-VEGF) agents, corticosteroids, and laser photocoagulation. However, emerging therapeutic strategies aimed at inhibiting EndMT and its downstream effects show promise in preventing the development and progression of DR. Understanding the molecular and cellular mechanisms underlying EndMT in DR provides valuable insights into the disease process and offers potential options for the development of potential treatments.
糖尿病视网膜病变(DR)是糖尿病(DM)患者高血糖引起的神经视网膜损伤的结果,是现代世界视力丧失的主要原因之一。这篇综述文章探讨了内皮细胞向间充质转化(EndMT)在糖尿病视网膜病变发病机制中的作用。内皮细胞向间质转化(EndMT)是导致DR的血液-视网膜屏障破坏、血管渗漏、新生血管形成和纤维化的原因之一。本文讨论了与 DR 严重程度相关的风险因素和生物标志物,强调了早期检测和靶向治疗的重要性。目前的治疗方法主要集中在抗血管内皮生长因子(anti-VEGF)药物、皮质类固醇和激光光凝上。然而,旨在抑制内膜生长因子及其下游效应的新兴治疗策略有望预防 DR 的发生和发展。了解 DR 中内膜种植的分子和细胞机制可为了解疾病过程提供宝贵的信息,并为开发潜在的治疗方法提供潜在的选择。